NDC 67046-651 Ranitidine

View Dosage, Usage, Ingredients, Routes, UNII

Product Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.
NDC Product Code:
67046-651
Proprietary Name:
Ranitidine
Product Type: [3]
INACTIVATED PRODUCT and EXCLUDED the from NDC Directory
Labeler Name: [5]
Contract Pharmacy Services-pa
Labeler Code:
67046
Start Marketing Date: [9]
06-30-2010
Listing Expiration Date: [11]
12-31-2021
Exclude Flag: [12]
I
Code Navigator:

Product Characteristics

Color(s):
ORANGE (C48331)
Shape:
ROUND (C48348)
Size(s):
9 MM
Imprint(s):
IP;253
Score:
1

Product Packages

NDC Code 67046-651-07

Package Description: 7 TABLET in 1 BLISTER PACK

NDC Code 67046-651-14

Package Description: 14 TABLET in 1 BLISTER PACK

NDC Code 67046-651-15

Package Description: 15 TABLET in 1 BLISTER PACK

NDC Code 67046-651-20

Package Description: 20 TABLET in 1 BLISTER PACK

NDC Code 67046-651-21

Package Description: 21 TABLET in 1 BLISTER PACK

NDC Code 67046-651-28

Package Description: 28 TABLET in 1 BLISTER PACK

NDC Code 67046-651-30

Package Description: 30 TABLET in 1 BLISTER PACK

NDC Code 67046-651-60

Package Description: 60 TABLET in 1 BLISTER PACK

Product Details

What is NDC 67046-651?

The NDC code 67046-651 is assigned by the FDA to the product Ranitidine which is product labeled by Contract Pharmacy Services-pa. The product's dosage form is . The product is distributed in 8 packages with assigned NDC codes 67046-651-07 7 tablet in 1 blister pack , 67046-651-14 14 tablet in 1 blister pack , 67046-651-15 15 tablet in 1 blister pack , 67046-651-20 20 tablet in 1 blister pack , 67046-651-21 21 tablet in 1 blister pack , 67046-651-28 28 tablet in 1 blister pack , 67046-651-30 30 tablet in 1 blister pack , 67046-651-60 60 tablet in 1 blister pack . This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information and RxNorm crosswalk.

What are the uses for Ranitidine?

Ranitidine Tablets, USPĀ are indicated in:Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks.Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year.The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis).Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks.Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year.Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets, USP 150 mg b.i.d.Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets, USP 150 mg q.i.d.Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks.Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis.

Which are Ranitidine UNII Codes?

The UNII codes for the active ingredients in this product are:

What is the NDC to RxNorm Crosswalk for Ranitidine?

RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:

* Please review the disclaimer below.

Product Footnotes

[5] What is the Labeler Name? - Name of Company corresponding to the labeler code segment of the Product NDC.

[9] What is the Start Marketing Date? - This is the date that the labeler indicates was the start of its marketing of the drug product.

[11] What is the Listing Expiration Date? - This is the date when the listing record will expire if not updated or certified by the product labeler.

[12] What is the NDC Exclude Flag? - This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".